Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Levi Groen"'
Autor:
Emmy Boerrigter, Guillemette E. Benoist, Inge M. vanOort, Gerald W. Verhaegh, Onno vanHooij, Levi Groen, Frank Smit, Irma M. Oving, Pieter deMol, Tineke J. Smilde, Diederik M. Somford, Niven Mehra, Jack A. Schalken, Nielka P. vanErp
Publikováno v:
Molecular Oncology, Vol 15, Iss 9, Pp 2453-2465 (2021)
Circulating RNAs extracted from liquid biopsies represent a promising source of cancer‐ and therapy‐related biomarkers. We screened whole blood from patients with metastatic castration‐resistant prostate cancer (mCRPC) following their first‐l
Externí odkaz:
https://doaj.org/article/fb1953ab5356432393af69c51aeab14a
Autor:
Levi Groen, Viktor Yurevych, Harshitha Ramu, Johnny Chen, Lianne Steenge, Sabrina Boer, Renske Kuiper, Frank P. Smit, Gerald W. Verhaegh, Niven Mehra, Jack A. Schalken
Publikováno v:
Non-Coding RNA, Vol 8, Iss 6, p 81 (2022)
Castration resistance is the leading cause of death in men with prostate cancer. Recent studies indicate long noncoding RNAs (lncRNAs) to be important drivers of therapy resistance. The aim of this study was to identify differentially expressed lncRN
Externí odkaz:
https://doaj.org/article/b4d5377139084d0a8924341a18aefeb2
Autor:
Levi Groen, Jack Schalken
Publikováno v:
European Urology Focus, 8, 4, pp. 904-906
European Urology Focus, 8, 904-906
European Urology Focus, 8, 904-906
Contains fulltext : 287574.pdf (Publisher’s version ) (Open Access) Urinary liquid biopsy (LB) tests have contributed to reducing overtreatment and improving the detection of bladder and prostate cancer. Circulating tumor cells, DNA, and RNA are th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fbecf44f2c10a10a029914f96293606
https://hdl.handle.net/2066/287574
https://hdl.handle.net/2066/287574
Autor:
Tineke J. Smilde, Frank Smit, Irma M. Oving, Guillemette E. Benoist, D.M. Somford, O. van Hooij, Gerald W. Verhaegh, P. De Mol, J.A. Schalken, N. P. van Erp, I.M. van Oort, Niven Mehra, Levi Groen, Emmy Boerrigter
Publikováno v:
Molecular Oncology, 15, 9, pp. 2453-2465
Molecular Oncology, 15, 2453-2465
Molecular Oncology
Molecular Oncology, Vol 15, Iss 9, Pp 2453-2465 (2021)
Molecular Oncology, 15, 2453-2465
Molecular Oncology
Molecular Oncology, Vol 15, Iss 9, Pp 2453-2465 (2021)
Circulating RNAs extracted from liquid biopsies represent a promising source of cancer‐ and therapy‐related biomarkers. We screened whole blood from patients with metastatic castration‐resistant prostate cancer (mCRPC) following their first‐l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d7e695322439948eb2df235ab2fbdd5
https://doi.org/10.1002/1878-0261.12933
https://doi.org/10.1002/1878-0261.12933
Publikováno v:
Expert Review of Molecular Diagnostics, 20, 2, pp. 219-230
Expert Review of Molecular Diagnostics, 20, 219-230
Expert Review of Molecular Diagnostics, 20, 219-230
Contains fulltext : 218088.pdf (Publisher’s version ) (Open Access) Introduction: Prostate cancer (PCa) is one of the most common malignancies in men and a major cause of cancer deaths among men worldwide. Prostate specific antigen (PSA) monitoring
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94ba5c45de0b59f47a34e23bfea3e2a5
https://doi.org/10.1080/14737159.2019.1675515
https://doi.org/10.1080/14737159.2019.1675515
Autor:
Frank Smit, Winald R. Gerritsen, Levi Groen, Paul Hamberg, Emmy Boerrigter, Jack A. Schalken, Onno van Hooij, Inge M. van Oort, Diederik M. Somford, Niven Mehra, Gerald W. Verhaegh, Guillemette E. Benoist, Pieter de Mol, Vincent O. Dezentjé, Nielka P. van Erp
Publikováno v:
Clinical Chemistry, 66, 842-851
Clinical Chemistry, 66, 6, pp. 842-851
Clinical Chemistry, 66, 6, pp. 842-851
Background Several treatment options were recently added for metastatic castration-resistant prostate cancer (mCRPC). However, response to therapy is variable, and biomarkers that can guide treatment selection and response evaluation are lacking. Cir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b159fdeec6aa937f105f93e0eefaf8d6
https://doi.org/10.1093/clinchem/hvaa095
https://doi.org/10.1093/clinchem/hvaa095
Autor:
Gerald Verhaegh, Diederik M. Somford, Tineke J. Smilde, Frank Smit, Levi Groen, Nielka P. van Erp, Onno van Hooij, Emmy Boerrigter, Inge M. van Oort, Pieter de Mol, Irma M. Oving, Guillemette E. Benoist, Niven Mehra, Jack A. Schalken
Publikováno v:
Cancer Research. 80:1413-1413
Background Abiraterone acetate is registered for treatment of metastatic prostate cancer, including those with castration-resistant disease (mCRPC). Although it improves overall survival and progression free survival (PFS), treatment response differs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f4bb1b100f508076bd354737d7ccb15a
https://doi.org/10.1158/1538-7445.am2020-1413
https://doi.org/10.1158/1538-7445.am2020-1413